Advertisement

Document › Details
Eckert & Ziegler SE. (12/13/24). "Press Release: Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW". Berlin.
![]() |
Region | Japan |
![]() |
Organisation | Eckert & Ziegler Radiopharma GmbH |
Group | Eckert & Ziegler (Group) | |
Organisation 2 | Novartis Pharma K.K. (NPKK) | |
Group | Novartis (Group) | |
![]() |
Product | GalliaPharm® 68Ge/68Ga Radionuclide Generator |
Product 2 | radionucleotide therapy | |
![]() |
Person | Schöpflin, Jan (Eckert & Ziegler 202412 Marketing) |
Person 2 | Riehle, Karolin (Eckert & Ziegler 202212 Investor Relations + PR) | |
Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68Ge/68Ga Radionuclide Generator for approval in Japan. This will pave the way for broader access to cutting-edge diagnostic tools including 68Ga-PSMA-11 in Japan. For GalliaPharm®, Novartis Pharma K.K., will manage safety information and distribution of the product in Japan.
GalliaPharm® is widely used as a high-quality GMP grade generator for Gallium-68, supporting the production of radiopharmaceuticals for positron emission tomography (PET) imaging, particularly in oncology including the diagnosis of prostate cancer through PSMA imaging. An approval in Japan will provide the local healthcare community with an accessible and reliable tool to label Gallium-68 radiopharmaceuticals, offering new precision in diagnostic imaging that may improve early disease detection and patient outcomes.
“This step with the MHLW for us is a critical one,” stated Dr. Deljana Werner, Head of QA and Regulatory Affairs for the Medical Division of Eckert & Ziegler SE. “As a company committed to advancing nuclear medicine globally, we see GalliaPharm®’s entry into the Japanese market as a pivotal opportunity to support medical professionals in enhancing patient care through precise and innovative imaging solutions.”
By seeking approval in Japan, Eckert & Ziegler reinforces its commitment to meeting the specific needs of diverse healthcare markets, tailoring its innovations to support local advancements in nuclear medicine. This step not only underscores the company’s dedication to providing advanced radioisotopes for medical applications worldwide, but also strengthens its position as a trusted partner in the evolving landscape of radiopharmaceuticals.
About Eckert & Ziegler SE
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler SE shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
[email protected] / [email protected]
Tel.: +49 (0) 30 / 94 10 84-138; https://ezag.com
Record changed: 2025-01-21 |
Advertisement

More documents for Eckert & Ziegler (Group)
- [1] Eckert & Ziegler SE. (1/14/25). "Press Release: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture". Berlin....
- [2] Eckert & Ziegler SE. (1/13/25). "Press Release: Eckert & Ziegler and GlyTherix Extend Collaboration with Actinium-225 Supply Agreement". Berlin & Sydney....
- [3] Eckert & Ziegler SE. (12/5/24). "Press Release: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments". Berlin....
- [4] Eckert & Ziegler SE. (12/3/24). "Press Release: Eckert & Ziegler – Changes in the Executive Board and Supervisory Board". Berlin....
- [5] Eckert & Ziegler AG. (1/8/24). "Press Release: Eckert & Ziegler and ArtBio Announce Manufacturing and Supply Partnership for Lead-212 Conjugates". Berlin & Cambridge, MA....
- [6] Eckert & Ziegler AG. (11/14/23). "Press Release: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes". Berlin....
- [7] Eckert & Ziegler AG. (9/25/23). "Press Release: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma". Berlin....
- [8] Eckert & Ziegler AG. (5/15/23). "Press Release: Reorganization in the Executive Board of Eckert & Ziegler". Berlin....
- [9] Eckert & Ziegler AG. (4/4/23). "Press Release: Eckert & Ziegler to Supply Point Biopharma with Actinium-225". Berlin & Indianapolis, IN....
- [10] Eckert & Ziegler Strahlen- und Medizintechnik AG. (12/19/22). "Press Release: Changes in the Management Board of Eckert & Ziegler. Insider Information Pursuant to Article 17 MAR". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top